HomeCompareYUXXF vs PFE

YUXXF vs PFE: Dividend Comparison 2026

YUXXF yields 10.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 YUXXF wins by $436203.75M in total portfolio value
10 years
YUXXF
YUXXF
● Live price
10.00%
Share price
$0.10
Annual div
$0.01
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$436203.80M
Annual income
$427,982,070,990.02
Full YUXXF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — YUXXF vs PFE

📍 YUXXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodYUXXFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, YUXXF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
YUXXF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

YUXXF
Annual income on $10K today (after 15% tax)
$850.00/yr
After 10yr DRIP, annual income (after tax)
$363,784,760,341.52/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, YUXXF beats the other by $363,784,738,021.61/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of YUXXF + PFE for your $10,000?

YUXXF: 50%PFE: 50%
100% PFE50/50100% YUXXF
Portfolio after 10yr
$218101.93M
Annual income
$213,991,048,624.37/yr
Blended yield
98.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

YUXXF
No analyst data
Altman Z
0.2
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

YUXXF buys
0
PFE buys
0
No recent congressional trades found for YUXXF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricYUXXFPFE
Forward yield10.00%6.13%
Annual dividend / share$0.01$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$436203.80M$49.6K
Annual income after 10y$427,982,070,990.02$26,258.71
Total dividends collected$435647.34M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: YUXXF vs PFE ($10,000, DRIP)

YearYUXXF PortfolioYUXXF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$12,700$2,000.00$9,153$693.39+$3.5KYUXXF
2$18,337$4,747.66$8,593$849.25+$9.7KYUXXF
3$32,433$12,812.76$8,336$1,066.78+$24.1KYUXXF
4$77,063$42,359.97$8,437$1,384.80+$68.6KYUXXF
5$270,590$188,131.85$9,013$1,875.40+$261.6KYUXXF
6$1,524,261$1,234,730.29$10,306$2,680.72+$1.51MYUXXF
7$14,631,657$13,000,698.03$12,820$4,101.38+$14.62MYUXXF
8$248,919,512$233,263,638.51$17,673$6,826.70+$248.90MYUXXF
9$7,683,863,097$7,417,519,219.51$27,543$12,591.86+$7683.84MYUXXF
10$436,203,804,504$427,982,070,990.02$49,560$26,258.71+$436203.75MYUXXF

YUXXF vs PFE: Complete Analysis 2026

YUXXFStock

Yuexiu Real Estate Investment Trust ("Yuexiu REIT") was listed on the Hong Kong Stock Exchange of Hong Kong Limited on 21 December 2005 and is the first listed real estate investment trust only investing in properties in the People's Republic of China (the "PRC") in the world. Yuexiu REIT focuses on office, retail and other commercial purposes, strives for properties which can bring considerable cash flows and returns and identifies business opportunities for achieving higher revenue growth through the optimization of its operations. The current property portfolio comprises eight high quality properties, namely White Horse Building, Fortune Plaza, City Development Plaza, Victory Plaza, Guangzhou International Finance Center in Guangzhou, Yuexiu Tower in Shanghai, Wuhan Properties in Wuhan and Victory Business Centre in Hangzhou, with a total area of ownership of approximately 973,001 square metres. All properties are located in the central business district ("CBD") of Guangzhou, Shanghai, Wuhan and Hangzhou respectively. The categories of the properties include professional clothing market, Grade-A offices, multiple functional commercial offices, retail business, hotel and serviced apartments etc. The Manager of Yuexiu REIT is Yuexiu REIT Asset Management Limited ("Manager"). Yuexiu REIT is managed by an experienced professional team with extensive experience in real estate management, asset management and the securities market and brings long-term and steady investment incomes to the Unitholders ("Unitholders") of Yuexiu REIT through actively managing its assets and expanding its operations. While the real estate investment trust market is flourishing, the Manager is committed to becoming a professional asset management institution with a focus on the PRC commercial property market, continuing asset appreciation capability, commercial operation capability, capital operation capability and a leading position in the industry.

Full YUXXF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this YUXXF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

YUXXF vs SCHDYUXXF vs JEPIYUXXF vs OYUXXF vs KOYUXXF vs MAINYUXXF vs JNJYUXXF vs MRKYUXXF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.